XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair value measurement - Contingent Consideration (Details)
$ in Thousands, € in Millions
3 Months Ended 12 Months Ended
Mar. 31, 2024
USD ($)
Mar. 31, 2024
EUR (€)
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Mar. 31, 2024
EUR (€)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Contingent consideration, net of current portion $ 14,625     $ 14,795  
Changes in fair value of contingent consideration 165   $ 975    
Contingent consideration 42,200     43,000  
Current portion of contingent consideration $ 27,587     28,211  
One hundred percent likelihood of AMT-260 advancing into clinical development          
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Percentage of increase in Probability of Success 100.00% 100.00%      
Changes in fair value of contingent consideration $ 74,800        
uniQure France [S.A.S]          
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Contingent consideration, net of current portion $ 42,212     $ 43,006  
Percentage of increase in Probability of Success 100.00% 100.00%      
Milestone payment achieving due to increase In Probability Of Success In Clinical Development $ 32,400 € 30.0      
Changes in fair value of contingent consideration 165        
uniQure France [S.A.S] | Maximum          
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Contingent consideration payable upon achievement of contractually defined milestones $ 193,000       € 178.8
Contingent consideration discount rate percentage 15.60% 15.60%   15.60%  
uniQure France [S.A.S] | Minimum          
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]          
Contingent consideration discount rate percentage 14.80% 14.80%   15.30%